Nicoline Hoogerbrugge - Selected Publications#

Researcher ID: O-1016-2013
Records in Pubmed 264
Web of Science H:index 43
Number of times cited: 6958

1. Grolleman, Judith E, de Voer, Richarda M. et al, Hoogerbrugge, Nicoline* and Kuiper, Roland*. Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-Tumor Phenotype Including a Predisposition to Colon and Breast Cancer. Cancer Cell 2019;35:256-266. * shared last author.
Impact factor 22,8 ; 0 citations

This study shows the value of mutational signatures in clinical cancer genetics.

2. Diets I, Waanders E, Ligtenberg MJL, Bladel DV, Kamping EJ, Hoogerbrugge PM, Hopman S, Olderode-Berends MJW, Gerkes EH, Koolen D, Marcelis C, Santen GW, Belzen MV, Mordaunt D, McGregor L, Thompson E, Kattamis A, Pastorczak A, Mlynarski W, Ilencikova D, Vulto-van Silfhout A, Gardeitchik T, de Bont ESJM, Loeffen J, Wagner A, Mensenkamp AR, Kuiper RP, Hoogerbrugge N*, Jongmans M*. High yield of pathogenic germline mutations causative or likely causative of the cancer phenotype in selected children with cancer. Clin Cancer Res. 2018; 24: 1594-1603. * shared last author.
Impact factor 10,2 ; 3 citations

This study shows the large contribution of germline genetics to pediatric cancer

3. Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet. 2016; 24: 881-8.
Impact factor 4,3 ; 22 citations

This study was the first to show how clinical genetic management of patients can effectively and safely change.

4. Weren RD, Ligtenberg MJL, Kets CM, de Voer RM, Verwiel ETP, Spruijt L, van Zelst-Stams WAG, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA, Kamping EJ, Nagtegaal ID, Tops BBJ, Nagengast FM, Geurts van Kessel A, van Krieken JHJM, Kuiper RP, Hoogerbrugge N. Identification of a novel adenomatous polyposis and colorectal cancer predisposing gene. Nat Genet. 2015; 47: 668-71.
Impact factor 36,3 ; 105 citations

This study discloses the novel regulatory aspect of NTHL1 in colorectal polyposis.

5. Sie AS, Mensenkamp AR, Adang EM, Ligtenberg MJ, Hoogerbrugge N.

Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol. 2014; 25: 2001-7.
Impact factor 13,9, 12 citations

This review and cost effectiveness study changed the guideline of hereditary colorectal cancer in many countries.

6. Marlies J E Kempers, Roland P Kuiper, et al., Nicoline Hoogerbrugge, Marjolijn J L Ligtenberg. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011; 12: 49-55.
Impact factor 22,6 ; 124 citations

This study was the first to show the effects of EPCAM of cancers risks.

7. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41:112-7.
Impact factor 36,4 ; 389 citations

This study was the first to identify a new genetic mechanism of hereditary somatic inactivation in hereditary colorectal cancer.

8. Post van der RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet. 2010;47:464-70.
Impact factor: 5,7 ; Citations: 77

This study was the first to show that bladder cancer is part of Lynch syndrome.

9 Kievit W, de Bruin JH, Adang EM, Severens JL, Kleibeuker JH, Sijmons RH, Ruers TJ, Nagengast FM, Vasen HF, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005;54:97-102.
Impact factor: 17,0 ; Citations : 61

This study largely improved the clinical detection rate of patients with hereditary colorectal cancer, Lynch syndrome

10 Hoogerbrugge N, Bult P, De Widt-Levert LM, Beex LV, Kiemeney LA, Ligtenberg MJ, Massuger LF, Boetes C, Manders P, Brunner HG. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003; 21: 41-5.
Impact factor: 26,3 ; Citations: 74

This study shows the causative effect of BRCA mutations to premalignant breast lesions.

Imprint Privacy policy « This page (revision-4) was last changed on Wednesday, 3. July 2019, 13:48 by System
  • operated by